KRYS stock has increased by 15% over the past month due to high demand for Vyjuvek and positive developments in their pipeline. We feel positive about the stock's future as we see potential for more growth.
KRYS stock has increased by 15% over the past month due to high demand for Vyjuvek and positive developments in their pipeline. We feel positive about the stock's future as we see potential for more growth.
Krystal Biotech has received a favorable opinion from the CHMP, suggesting that Vyjuvek should be approved for the treatment of dystrophic epidermolysis bullosa in the European Union.
PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company in the commercial stage, is pleased to announce that the European Medicines Agency (EMA) has recommended the approval of VYJUVEK® (beremagene geperpavec-svdt, or B-VEC) for treating wounds in patients with dystrophic epidermolysis bullosa (DEB) who have specific mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. The positive opinion from the Committee for Medicinal Products for Human Use (CHMP) also supports the use of VYJUVEK in healthcare settings.
Krystal Biotech (KRYS) shares have begun to rise and may keep increasing soon, based on positive changes in earnings forecasts.
Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.
Krystal Biotech (KRYS) has received a Zacks Rank #2 (Buy) upgrade, indicating increased confidence in the company's potential earnings. This could lead to a rise in the stock price soon.
Krystal Biotech's VYJUVEK is experiencing significant growth, with sales projected to surpass $1 billion in 2025 due to its launches in the EU and Japan. Although the company's Q4 earnings exceeded earnings per share expectations, they fell short of revenue predictions; nonetheless, the positive outlook for 2025 led to a surge in share prices. Important events for 2025 include the launches of VYJUVEK in the EU and Japan, results from Phase 3 ocular DEB trials, and advancements in cystic fibrosis and lung gene therapy.
KRYS stock rises even though the company had mixed results for the fourth quarter, as the launch of its main drug, Vyjuvek, in the United States is seeing good demand.
PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), which uses Krystal's gene-delivery technology to tackle aging skin, has announced the appointment of Nishant Saxena as Chief Financial Officer (CFO), starting January 15, 2025. Mr. Saxena brings more than 20 years of experience in finance, strategy, and corporate development. Most recently, he worked as a Managing Director in Evercore's healthcare group, where he advised on deals worth over $500 billion.